Stryker (SYK) announced it has received FDA 510(k) clearance for the Incompass Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone and Infinity systems into a single solution for total ankle replacement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $455 from $443 at Citi
- Stryker announces FDA 510(k) clearance for OptaBlate
- Stryker Shareholders Approve Amendments at Annual Meeting
- Stryker’s Strategic Moves and Strong Financial Outlook Justify Buy Rating with $435 Price Target
- Stryker price target raised to $400 from $390 at Truist